印度单日新增确诊轻微回落至25.9万宗 5月起容许所有18岁以上国民接种疫苗
印度周二(20日)新增新冠确诊个案轻微回落至25.92万宗,惟仍连续六日单日新增逾20万宗;累计逾1,532万宗。死亡个案增1,761宗创单日新高,累计死亡18.05万宗。
当地政府宣布,自5月1日起容许所有18岁以上国民接种新冠疫苗,原先仅45岁以上国民方可接种疫苗。由於疫情加剧,据《路透》报道,当地官员昨(19日)表示,将豁免对进口新冠疫苗的10%关税。当地自俄罗斯进口的Sputnik V疫苗快将抵步,政府亦促请辉瑞(PFE.US)、Moderna(MRNA.US)及强生(JNJ.US)向印度出售新冠疫苗。政府亦考虑容许私企进口获认可疫苗,在公开市场出售,并容许私企自行定价。现时印度政府规管当地疫苗所有采购及销售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.